Claraphi Advisory Network’s AstraZeneca AZN Stock Holding History

Claraphi Advisory Network’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,682	Closed	-$486K	–	200
2022 Q2	$486K	Buy	+3,682	New	+$483K	0.17%	140
2020 Q2	–	Sell	-144	Closed	-$13K	–	362
2020 Q1	$13K	Buy	+144	New	+$13.6K	0.01%	715

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Claraphi Advisory Network's AZN Position: Q3 2022 in Review

Claraphi Advisory Network sold out of AstraZeneca (AZN) in Q3 2022, closing a stake of 3,682 shares — an estimated $486K sold.

Claraphi Advisory Network first reported a position in AZN in Q1 2020 and held it in 2 quarters. The position peaked at $486K in Q2 2022. 966 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

Claraphi Advisory Network reported no remaining AstraZeneca position as of Q3 2022 after selling out during the quarter.
Claraphi Advisory Network sold 3,682 AstraZeneca shares in Q3 2022, an estimated $486K.
Claraphi Advisory Network first reported a position in AstraZeneca in Q1 2020 and held it in 2 quarters.
Claraphi Advisory Network's AstraZeneca position peaked at $486K in Q2 2022.
966 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on Claraphi Advisory Network's 13F filing for Q3 2022, filed 15 Nov 2022.